Arvinas
Price & Volume
Stats
See moreOpen | $6.21 |
Previous Close | $6.56 |
Day Range | $6.09-$6.45 |
52W Range | $6.24-$39.34 |
Market Cap | $451.1M |
Shares Short | 8M |
Financials
See moreRevenue (12 Mos) | $263.4M |
Revenue Growth (YoY) | 196% |
Gross Profit (12 Mos) | $263.4M |
Diluted EPS | -$2.77 |
News
See moreYahoo Finance • 4 days ago
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Yahoo Finance • 12 days ago
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Yahoo Finance • 28 days ago
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Yahoo Finance • last month
Arvinas to Participate in Upcoming Investor Conferences
About
CEO | Dr. John G. Houston Ph.D. |
CFO | Mr. Andrew R. Saik |
Address | 5 Science Park, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 430 |
